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Abstract
Background: Epidermal Growth Factor Receptor (EGFR) is a key target molecule in current
treatment of several neoplastic diseases. Hence, in order to develop and improve current drugs
targeting EGFR signalling, an accurate understanding of how this signalling pathway is regulated is
required. It has recently been demonstrated that inhibition of cAMP-dependent protein kinase
(PKA) induces a ligand-independent internalization of EGFR. Cyclic-AMP-dependent protein kinase
consists of a regulatory dimer bound to two catalytic subunits.
Results: We have investigated the effect on EGFR levels after ablating the two catalytic subunits,
Cα and Cβ in two different models. The first model used targeted disruption of either Cα or Cβ
in mice whereas the second model used Cα and Cβ RNA interference in HeLa cells. In both models
we observed a significant reduction of EGFR expression at the protein but not mRNA level.
Conclusion: Our results suggest that PKA may represent a target that when manipulated can
maintain EGFR protein levels at the single cell level as well as in intact animals.
Background
Ligand binding to EGFR induces tyrosine transphosphor-
ylation, and phosphotyrosines serve as binding sites for
various signalling molecules. Association of these mole-
cules with the EGFR leads to their activation, and initia-
tion of signalling cascades culminating in a variety of
responses. The activated EGFR is internalized shortly after
ligand binding, and is processed in the endosomal path-
way. The receptor is signalling competent when residing
in the plasma membrane [1], but also during intracellular
receptor trafficking [2,3]. Defects in the internalization
process and degradation pathways for the EGFR family
members have been associated with cell transformation
and oncogenesis [4]. It has been demonstrated that cAMP-
dependent protein kinase (PKA) is involved in the trans-
duction of mitogenic signals [5], and interactions between
PKA and the activated EGFR have been demonstrated [6].
Previous studies have shown that the EGFR is a substrate
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serine residues leads to decreased tyrosine kinase activity
and diminished autophosphorylation of the EGFR [9].
Recently, Salazar and Gonzalez [10] showed that PKA
basal activity controls EGFR function, both at the cell sur-
face and during down-regulation.
PKA is a holoenzyme consisting of two regulatory (R) sub-
units bound together in a dimer, with one catalytic (C)
subunit bound to each R-subunit [11]. In the absence of
cAMP, the R-subunits will inhibit the C subunits, but a
conformational change in the R-subunit is induced by
binding of cAMP, releasing the C subunit which is then
active. In mammals, four genes encode different isoforms
of the R-subunits, RIα, RIβ, RIIα and RIIβ, and three dif-
ferent genes encode three isoforms of C, Cα, Cβ and PRKX
[12]. The Cα and Cβ isoforms are closely related in pro-
tein sequence, whereas the PRKX sequence is divergent
from Cα and Cβ. The Cα and the Cβ genes encode tissue-
specifically expressed splice variants designated Cα1,
Cα2, Cβ1, Cβ2, Cβ3, Cβ4, and several Cβ3 and 4abc vari-
ants [13-20].
Functional features associated with the various C subunits
have been studied in genetically null mutated mice. Muta-
tion of the Cβ gene does not result in any clear phenotype
and the mice appear healthy and fertile [21]. By contrast,
mutation of the Cα gene leads to early postnatal lethality
in the majority of the offsprings [22]. The male Cα KO
mice that survive to adulthood are infertile and both male
and females show a uniform reduction in size by approx-
imately 30% compared to their wild type littermates. Size
reduction is accompanied by a nearly complete absence of
PKA C subunit activity in most tissues, except the brain,
where C subunit activity is slightly elevated due to Cβ
compensation. Moreover, growth retardation in the Cα
KO mice may be growth hormone (GH)-dependent
because mRNA levels of GH-dependent molecules such as
IGF-1 (insulin like growth factor 1) and MUPs (major uri-
nary protein) were significantly reduced.
The cAMP/PKA signaling pathway may be activated
through stimulation of a number of different receptors
that regulate a vast number of cellular processes. These
include metabolism, gene expression, ion channel con-
ductivity, cell growth and division as well as cell differen-
tiation [23,24]. Since the significance of PKA-dependent
interaction with the EGFR is poorly understood, we
embarked on a study to investigate the location and levels
of EGFR in PKA C subunit null mutated mice. Our results
indicate that the level and localization of EGFR are closely
correlated with the level and activities of PKA C subunit.
Results
EGFR levels in mice are regulated by PKA catalytic 
subunits
EGFR trafficking has been demonstrated to be regulated
by PKA activity, and inhibition of PKA activity results in
internalization of the EGFR in neuroblastoma N2a cells
[10]. We therefore decided to examine the localization of
EGFR in the livers of mice depleted of either PKA Cα or Cβ
[22,21]. Livers from wt and KO Cα and Cβ mice were dis-
sected and the morphology and size examined. As illus-
trated in Figure 1A, livers from Cα KO mice were smaller
compared to wt mice. Frozen sections of liver from wt and
KO of Cα and Cβ were stained using anti-EGFR and visu-
alized using confocal immunofluorescence microscopy.
We observed a reduction in membrane association as
compared to the wild-type littermates for both Cα KO and
Cβ KO (Figure 1B). This led us to believe that abolished
expression of either Cα or Cβ led to a decrease in total
EGFR levels in liver.
To test this hypothesis, cell extracts were prepared from
liver and brain of Cα and Cβ KO animals and wt and het-
erozygous littermates, separated by SDS-PAGE for analysis
by Western immunoblotting using anti-EGFR (Figure 1C,
upper panel). In liver but not brain, a clear reduction in
total EGFR could be observed in both Cα KO and Cβ KO
animals, as compared to their wild-type mice (Figure 1C,
upper panel). This was also demonstrated by immunohis-
tochemical staining of frozen brain sections (data not
shown). To correlate this to total PKA C expression, simi-
lar Western blots were analyzed using an anti-PKA C anti-
body, demonstrating a clear reduction of PKA
immunoreactive protein in both Cα KO and Cβ KO ani-
mals, as compared to their wild-type and heterozygous lit-
termates (Figure 1C, middle panel). The expression and
stability of another EGFR family member, ErbB2, was not
affected by PKA depletion (Figure 1C, lower panel), dem-
onstrating specificity of PKA-dependent regulation of the
EGFR. EGFR expression levels in heart, kidney, intestine
and lung tissue from mice was also analyzed, but due to
low EGFR protein levels we were unable to draw conclu-
sions regarding comparison of EGFR protein levels in wt
versus knock out animals (data not shown).
Our observation that Cβ KO animals displayed decreased
expression of EGFR was unexpected as previous results
have indicated that liver mainly expresses the Cα isoform
[25]. We therefore examined the total PKA activity in cell
extracts of livers from both Cα and Cβ KO animals and
their wt littermates using a Kemptide based phospho-
transferase assay (Figure 1D). Both Cα and Cβ KO ani-
mals demonstrated a similar reduction in total PKA
activity of more than 70%, indicating that both Cα and
Cβ contribute significantly to total PKA activity in mouse
liver.Page 2 of 9
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Effect of PKA Cα or Cβ ablation on EGFR expressionFigure 1
Effect of PKA Cα or Cβ ablation on EGFR expression. (a) Comparison of liver from wild type and PKA Cα and Cβ 
ablated mice. PKA Cα KO mice showed a clear uniform reduction in size. (b) Confocal immunofluorescence microscopy of 
frozen liver sections stained by sheep anti-EGFR and Cy3-conjugated donkey anti-sheep antibodies. (c) Western immunoblot-
ting analysis of EGFR expression in liver and brain from wt (+/+), heterozygote (-/+), and Cα and Cβ KO (-/-) mice. Immunob-
lots were incubated with sheep anti-EGFR, rabbit anti-pan PKA C and mouse anti-PKA C, and rabbit anti-erbB2. Secondary 
HRP-conjugated anti-IgG antibodies were used for detection. (d) PKA kinase activity in mouse liver. Activity was assayed by 
phosphorylation of the PKA-specific substrate Kemptide using γ-[32P]ATP. The assay was performed in the presence of cAMP. 
Activity was measured by liquid scintillation in 3 ml Opti-fluor. Values are given as counts per minute (cpm).
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including at the level of transcription, mRNA processing,
translation as well as post translation. In order to examine
how the EGFR level is regulated, we compared the EGFR
mRNA levels in liver of wild type animals with Cα and Cβ
KO animals, using real-time PCR.
Deficiency of the PKA Cα or Cβ isoforms did not change
expression of EGFR mRNA (Figure 2A,B, respectively).
This demonstrated that the reduction in EGFR-levels in
Cα and Cβ KO mice livers was not due to reduced mRNA
expression, and indicates that a modulation of EGFR at
post-transcriptional level is responsible for the reduction
in EGFR.
Ablation of PKA Cα or Cβ reduces the growth in mice
Previously it has been reported that Cα KO mice are
growth retarded and thus have significantly reduced body
size compared to their wild type littermates [22]. In this
study an early postnatal lethality in the majority of Cα KO
mice was reported. However, a small percentage of Cα KO
mice survived to adulthood [22]. From our preliminary
studies with Cα KO mice, we hypothesized that there was
a link between body size reduction and a reduced EGFR
expression level in these animals. Previous studies did not
detect any obvious differences in phenotype of Cβ KO
mice [21]. In order to examine if there are any decreases in
body size for the Cβ mice, we compared body weight of
wt, Cα and Cβ mice at different ages using multiple linear
regression in SPSS. As expected, the Cα KO mice were sig-
nificantly smaller (P < 0.0001) than their wt littermates at
all ages (Figure 3). The analysis showed a significant cor-
relation between body weight and genotype when
adjusted for age (P < 0.0001). This was also the case with
the Cβ KO mice (P < 0.0001). It should however be men-
tioned that this reduction was much less profound when
compared to the Cα KO littermates. Based on this we sug-
gest a redundant function of Cα and Cβ in regulating
body size which may be associated with reduced expres-
sion of EGFR.
PKA Cα and Cβ are involved in the regulation of EGFR 
expression in HeLa cells
In order to further substantiate the correlation between
depletion of PKA catalytic isoforms and expression of the
EGFR protein, we studied HeLa cells treated with siRNA
directed against Cα and Cβ. Following 24 h incubation
with either Cα or Cβ-specific siRNA PKA specific kinase
activity was measured by a Kemptide based phospho-
transferase assay. This demonstrated a 30% reduction in
PKA kinase activity (Figure 4A). When EGFR mRNA levels
in the same samples were analyzed by RT-PCR, it was clear
that the reduced activity of PKA did not result in a down-
regulation of EGFR mRNA (Figure 4B). In contrast the
protein level of EGFR was significantly decreased as meas-
ured by immunoreactive protein in cell extracts of control
cells and cells treated with siRNA against Cα and Cβ (C,
Cα and Cβ, respectively, Figure 4C).
Discussion
The data presented here have demonstrated in two differ-
ent models that depletion of Cα or Cβ induces a reduction
of EGFR protein levels, and that this reduction is not due
to decreased level of EGFR mRNA.
A recent report by [10] demonstrated that membrane
expression of EGFR was inhibited by the PKA inhibitor
EGFR mRNA expression in livers from wt, Cα and Cβ KO miceFigure 2
EGFR mRNA expression in livers from wt, Cα and Cβ 
KO mice. The level of EGFR cDNA was determined by real 
time RT-PCR. The levels of EGFR mRNA expression in Cα 
KO versus wt livers (a) and Cβ KO versus wt livers (b) were 
calculated as relative copy numbers normalized against 
GAPDH mRNA. Relative EGFR mRNA expression was cal-
culated using the formula (E/G) × 100, where E and G are the 
relative copy numbers of EGFR and GAPDH mRNA, respec-
tively. The results are given as +/- SEM where n = 3.Page 4 of 9
(page number not for citation purposes)
BMC Cell Biology 2008, 9:16 http://www.biomedcentral.com/1471-2121/9/16H89 through increased internalization and endosome
arrest of the EGFR in neuroblastoma N2a cells. Such an
effect could be observed after 4 hours of H89 treatment.
As H89 is known to have a broader inhibitory specificity
[26-28], these observations did not necessarily prove
involvement of PKA in maintaining EGFR levels. Here we
demonstrate that EGFR was reduced in both mouse liver
and HeLa cells after depletion of Cα and Cβ, respectively.
The reduced levels of EGFR were not due to reduction in
EGFR mRNA, as demonstrated in both HeLa cells
depleted of either Cα or Cβ, as well as mouse livers iso-
lated from Cα and Cβ KO mice. The results from mouse
Cα and Cβ KO livers indicated a relative reduction in
staining for EGFR along the plasma membrane, as well as
a general reduction of immunoreactive protein. This is
contrary to the previous observation that H89 and thus
inhibition of PKA induces an increased internalization of
EGFR, which suggests that reduced PKA activity leads to
degradation of EGFR. Our results demonstrate in mouse
liver as well as HeLa cells, that a reduction in total PKA
activity either through elimination of Cα or Cβ leads to a
reduced expression of EGFR protein. This was not
observed in the brain of neither Cα nor Cβ KO mice. The
explanation for this may be that brain has a much higher
levels of both PKA Cα and Cβ than liver and HeLa cells
[29,15]. Thus, one C subunit may be expected to compen-
sate for the loss of activity of the other isoform. Based on
that we postulate that protein levels of EGFR depend on a
certain threshold level of PKA and that this effect may not
be isoform-specific. Such a hypothesis is in part supported
by observations made by Huang and colleagues [30]. In
mice with one or two mutant C subunit alleles (Cα -/- and
Cβ +/+ or Cα+/+ and Cβ -/- or Cα-/+ and Cβ -/+), either
of them were born with apparent embryonic defects.
However, when deleting three alleles (either Cα -/- and Cβ
-/+, or Cα -/+ and Cβ -/-) they demonstrated a 100% pen-
etrant spinal neural tube defect and spina bifida. This sug-
gests that the C gene dose in the brain is sufficient to
Postnatal growth of Cα and Cβ KO mice: the figure depicts the correlation between age and measured body weight of WT mice (n = 76) versus Cα KO (n = 32) and Cβ KO (n = 42) micFigure 3
Postnatal growth of Cα and Cβ KO mice: the figure depicts the correlation between age and measured body 
weight of WT mice (n = 76) versus Cα KO (n = 32) and Cβ KO (n = 42) mice. Linear regression analysis showed that 
both Cα and Cβ KO mice have a significantly lower body weight when compared to WT mice (P < 0,0001) when adjusted for 
age.Page 5 of 9
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Levels of EGFR protein correlate with levels and activities of Cα and Cβ in HeLa cellsFigure 4
Levels of EGFR protein correlate with levels and activities of Cα and Cβ in HeLa cells. (a) HeLa cells incubated 
with RNAi against Cα and Cβ and monitored for PKA-specific phosphotransferase activity in cell extracts of 1 mg/mL. Relative 
values given as counts per minute (cpm). (b) Relative EGFR mRNA expression levels were measured by RT-PCR and are given 
as E/G × 100 where E and G are the relative copy numbers of EGFR and GAPDH mRNA, respectively. The results are given as 
+/- SEM where n = 3. (c) Western immunoblotting analysis of expression of EGFR and PKA C. An anti-actin antibody was 
applied to ensure equal loading.
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and Cβ redundancy in the brain. Furthermore, in our
experiments we observed that the regulatory effects on the
EGFR levels were apparent even without prior stimulation
of endogenous cAMP formation. This observation may be
explained in several ways including that of chronic levels
of endogenous cAMP, or free C subunits which activity is
stimulated independently of cAMP. The latter hypothesis
is supported by several studies demonstrating that C sub-
units when bound to proteins other than the PKA R subu-
nit, the C subunits may be regulated in a cAMP
independent fashion [31,32].
The fact that Cβ ablated mice also displayed decreased lev-
els of EGFR indicates that Cβ plays a role in mouse liver,
despite previous data indicating low levels of Cβ in mouse
liver [15]. This was further substantiated by measurement
of PKA activity in mouse liver, demonstrating reduced
activity in both Cα and Cβ KO livers. As the sensitivity of
Western blotting and mRNA measurements of Cα and Cβ
will vary, our measurements of activity in KO mice is
probably a better indication of the relative contribution of
total C activity from the different isoforms. The reduction
in C activity in Cα KO was 70%, while the reduction in C
activity in Cβ KO mice was also 70%. This can best be
explained by the presence of satiable PKA inhibitors, like
endogenous PKI.
The fact that EGFR levels were reduced in the liver of Cβ
KO mice is the first observation of a Cβ-dependent pheno-
type affecting non-nervous tissues. However, we were also
able to demonstrate a small but significant reduction in
size of the Cβ ablated mice compared to the wt mice, sug-
gesting that the Cβ subunit may influence growth regula-
tion as has been demonstrated for the Cα subunit. The Cα
ablated mice showed a growth retardation phenotype
consistent with disruption of the GH/IGF-I endocrine sys-
tem, and while GH-hormone levels were normal, IGF-I
mRNA and major urinary proteins (MUPs) levels were
reduced, indicating a partial resistance to GH [22]. It has
been reported that Cα ablated mice are reduced in size by
approximately 30% and approximately 90% die before
puberty [22]. Cβ ablated mice by contrast only show a
very small reduction in size and they also differ from the
Cα mice in that offspring normally survive to adulthood.
It is tempting to suggest that Cβ and Cα have redundant
effects. Moreover, this may also suggest that cellular sign-
aling pathways involved in growth regulation are merely
dependent on a certain level of PKA activity for proper
function, rather than isoform-specific effects of Cα and
Cβ. As Cα is the most abundant C subunit in non-nervous
tissues, disruption of Cα would result in more severe
effects in the whole animal than the ablation of the gene
for the less abundant Cβ subunit.
High levels of EGFR are associated with many tumors with
poor prognostic features. EGFR itself and its downstream
signalling pathways are promising targets for anti-tumour
drugs [33]. PKA has also been proposed as a possible tar-
get for cancer therapy, and the therapeutic potential of the
combined blockade of EGFR and PKA has been discussed
[34]. With respect to cancer therapy, the focus has been set
on the regulatory isoforms of PKA. Site-selective cAMP
analogue 8-Cl-cAMP and a series of modified antisense
oligonucleotides targeting the PKA RIα subunit have been
applied without conclusive effects [35-37]. However, the
effects of the cAMP analog 8-Cl-cAMP may be mediated
by metabolite rather than the cAMP analog itself, suggest-
ing that PKA is not involved.
Conclusion
The data presented here have demonstrated in two differ-
ent models that depletion of Cα or Cβ induces a reduction
of EGFR protein levels, and that this reduction is not due
to decreased level of EGFR mRNA. Our results have dem-
onstrated that PKA activity contributes to maintaining
EGFR levels in cells and in vivo, thus suggesting a cross-
talk between the cAMP and EGF pathways, making the
PKA C subunit a potential target for future therapies.
Methods
Breeding and genotyping of PKA Cα and Cβ null mutated 
mice
Mice ablated (knock-out, KO) for the Cα, and Cβ genes
were kindly contributed by Professor G. Stanley Mck-
Knight (Department of Pharmacology, University of
Washington School of Medicine, Seattle, 98195, USA.)
[22,21]. All use of animals has been approved and regis-
tered by the Norwegian Animal Research Authority. The
mice strains were both on a mixed C57BL/6 × 129 back-
ground and were treated and bread identically. Animals
were housed in a temperature controlled (22°C) facility
with a strict 12 hour light/dark cycle, and allowed the
RM1 diet (Special Diet Services Ltd, Witham, Essex, UK)
and water ad libitum before euthanasia. Heterozygote ani-
mals were crossed and offspring genotyped by PCR. The
Cα and Cβ KO allele were detected as previously
described [22,38].
Immunofluorescence microscopy
Immunohistochemical analysis of EGFR distribution and
expression in liver sections from 6 weeks old wild type
and PKA Cα and Cβ KO mice was performed on 8 μm
thick sections fixed in ethanol as described previously
[39]. Sections were incubated with a sheep anti-EGFR
antibody (Fitzgerald) over night, following detection with
a Cy2-conjugated donkey anti-sheep IgG antibody (Jack-
son Immunoresearch). Sections were examined using a
Leica TSC XP confocal microscope (Leica Microsystems)
equipped with an Ar (488 nm) and two He/Ne (543 andPage 7 of 9
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was used.
Western immunoblotting analysis
Liver and brain from 6 weeks old mice, and HeLa cells,
were lysed in Tris lysis buffer, pH 7.4 (50 mM Tris-HCl,
150 mM NaCl, 1 mM EDTA, 1% NP-40, 1 mM Na3VO4,
20 mM NaF, 1 μg/ml chymostatin, leupeptin and
antipain. Liver and brain were homogenized using a Mini
beadbeater (Biospec products) with 1 mm silica beads for
20 sec at 4°C. Lysates were incubated on ice for minimum
15 min, and cell debris and nuclei removed by centrifuga-
tion at 8000 rpm at 4°C for 10 min. The Dc protein detec-
tion kit was applied to measure and adjust total protein
concentrations. A 5× protein sample buffer stock solution
(2% SDS, 10% glycerol, 0.02% bromophenol blue and
2% β-mercaptoethanol, final concentrations) was mixed
with the lysates. The samples were boiled for 5 min, and
proteins separated by SDS-PAGE in 6% and 10% gels. Pro-
teins were transferred wet to nitrocellulose membranes,
rinsed in ice-cold Tris-buffered saline [TBS; 10 mM Tris,
pH 8.0, and 150 mM NaCl] and incubated in blocking
buffer (TBS containing 5% dry milk) for 30 min at RT. The
membranes were incubated over night at 4°C with don-
key anti-EGFR (Fitzgerald), rabbit anti-pan C (anti-PKAα
cat, Santa Cruz biotechnology) and mouse anti-PKA C
(BD Biosciences), and anti-erbB2 (Zymed). Immunoreac-
tive proteins were recognized using anti-sheep IgG and
rabbit IgG conjugated to HRP (Jackson Immunoresearch
and Sigma, respectively). Proteins were detected using
HRP-conjugated donkey anti-sheep IgG and anti-mouse
IgG (Jackson Immunoresearch), and goat anti-rabbit IgG
(Sigma) for 90 min at RT. All antibodies were diluted in
TBS containing 1% w/v dry milk and 0.01% thimerosal.
The filters were washed in TBS, and antigens were visual-
ized by the enhanced chemiluminescence (ECL) method
with Hyperfilm MP (Amersham Biosciences).
Phosphotransferase assay
The PKA kinase activity in liver or HeLa cell was assayed
by phosphorylation of the PKA-specific substrate Kemp-
tide (Peninsula Laboratories) using γ-[32P]ATP (Amer-
sham Biosciences). The assay was performed in the
presence of cAMP. Cells were washed in PBS, harvested by
scraping, solubilised in 200 μl homogenising buffer (5
mM KH2PO4, 5 mM K2HPO4, 1 mM EDTA, 250 mM
sucrose and protease inhibitor cocktail (Roche Diagnos-
tics), pH 6.8) and sonicated for 3 × 5 s. The homogenate
was cleared by centrifugation at 16,000 × g for 10 min at
4°C. Total protein amount was estimated by Dc protein
assay (BioRad). Ten-micro liter homogenate was used in
an assay mixture earlier described [40]. Reactions were
performed at 30°C, and stopped after 9 min by transfer to
P81 phosphocellulose paper (Whatman). Filters were
washed in 75 mM phosphorus acid for 1 h at room tem-
perature, incubated with 96% ethanol for 10 min and
dried. Activity was measured by liquid scintillation in 3
ml Opti-fluor™ (Packard BioScience).
RT-PCR
Mouse liver from 6 weeks old mice was homogenized as
described above. HeLa cells were washed in PBS, har-
vested by scraping and subjected to total RNA isolation
using the RNeasy Minikit (Qiagen). RNA (1 μg) was used
to make first-strand cDNA by Reverse Transcription sys-
tem (Promega). Titration with cDNA was performed dem-
onstrating that the method was able to detect small
changes in sample size. The cDNA was used as templates
in PCRs with primer combinations specific for mouse
EGFR (5'-TCT TCA AGG ATG TGA AGT GTG-3', 5'-TGT
ACG CTT TCG AAC AAT GT-3'). Human EGFR Primers
used for EGFR amplification in HeLa cells were: 5'-GCC
AAG GCA CGA GTA ACA AGC-3', 5'-AGG GCA ATG AGG
ACA TAA CC-3'. The PCR reaction was carried out in a 20
μl final volume containing the following: H2O up to 20μl; 2.4 μl 25 mmol/l MgCl2; 1 μl 10 pmol sense primer, 1μl 10 pmol antisense primer, 2 μl LC-Faststart master mix,
and 4 μl cDNA. PCR cycles were as follows: 94°C for 120
s (initial denaturation), 95°C for 5 s, 58°C for 5 s, and
72°C for 13 s (45 cycles).
Cell culture and RNAi transfection
HeLa cells were cultured in Dulbecco's modified Eagle's
medium supplemented with 10% fetal bovine serum
(Gibco-BRL), 2 mM l-glutamine and maintained at 37°C
and 5% CO2. The cells were seeded in 60-mm dishes and
all transfections and experiments were initiated two days
after plating. Two siRNA duplexes protected by two 3'-
overhanged (2'-deoxy) thymidines (dT) were synthesized
by Dharmacon Research. These oligonucleotides are: PKA
Cα: 5'-AAG CUC CCU UCA UAC CAA AGU-3', PKA Cβ:
5'-AAG GUC CGA UUC CCA UCC CAC-3'. HeLa cells
were transiently transfected with siRNA against PKA Cα
and Cβ using lipofectamine 2000 (Invitrogen) in Opti-
mem medium (Gibco) at the final concentration of 115
nM. Nontargeting (scrambled) siRNA pool (Dharmacon)
at the same concentration was used as a control. After 24
h transfection, cell lysates were collected with Tris lysis
buffer and total protein concentration was estimated and
adjusted by Dc protein assay (Bio-Rad).
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